


PHARMACEUTICAL 2022

Kinnate Biopharma Inc. Rank 135 of 475





PHARMACEUTICAL 2022

Kinnate Biopharma Inc. Rank 135 of 475

The relative strengths and weaknesses of Kinnate Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kinnate Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Kinnate Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 13%, being 289% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	258,690
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,387
Liabilities, Non-Current	0
Other Assets	107,218
Other Compr. Net Income	-515
Other Expenses	0
Other Liabilities	0
Other Net Income	348
Property and Equipment	956
Research and Development	67,166
Revenues	0
Selling, General and Administrative Expense	22,945

Output Variable	Value in 1000 USD
Assets	366,864
Liabilities	12,387
Expenses	90,111
Stockholders Equity	354,477
Net Income	-89,763
Comprehensive Net Income	-90,020
Economic Capital Ratio	13%